
A meta-analysis of weekly cisplatin versus three weekly cisplatin chemotherapy plus concurrent radiotherapy (CRT) for advanced head and neck cancer (HNC)


SUPPLEMENTARY FIGURES

weekly cisplatin		three weekly cisplatin		Risk Ratio		Risk Ratio		
Events	Total	Events	Total	Weight	M-H, Fixed, 95% Cl	M-H, Fix	ed, 95% CI	
5	32	4	51	13.2%	1.99 [0.58, 6.87]	_	-	
5	24	6	27	24.2%	0.94 [0.33, 2.68]			
1	33	8	32	34.8%	0.12 [0.02, 0.91]		-	
3	45	1	28	5.3%	1.87 [0.20, 17.07]		-	
1	24	0	26	2.1%	3.24 [0.14, 75.91]		· ·	
3	20	6	30	20.5%	0.75 [0.21, 2.66]			
	178		194	100.0%	0.85 [0.49, 1.48]	•		
18		25						
Heterogeneity: Chi ² = 6.63, df = 5 (P = 0.25); I^2 = 25%							1 10	100
Test for overall effect: $Z = 0.57$ (P = 0.57)								100 weekly
	5 5 1 3 1 3 3 1 3 63, df = 5 (P	Events Total 5 32 5 24 1 33 3 45 1 24 3 20 178 18 63, df = 5 (P = 0.25)	Events Total Events 5 32 4 5 24 6 1 33 8 3 45 1 1 24 0 3 20 6 178 18 25 63, df = 5 (P = 0.25); l² = 25%	Events Total Events Total 5 32 4 51 5 24 6 27 1 33 8 32 3 45 1 28 1 24 0 26 3 20 6 30 178 194 18 25 63, df = 5 (P = 0.25); l² = 25%	Events Total Events Total Weight 5 32 4 51 13.2% 5 24 6 27 24.2% 1 33 8 32 34.8% 3 45 1 28 5.3% 1 24 0 26 2.1% 3 20 6 30 20.5% 178 194 100.0% 18 25 63, df = 5 (P = 0.25); ² = 25%	Events Total Events Total Weight M-H, Fixed, 95% C 5 32 4 51 13.2% 1.99 [0.58, 6.87] 5 24 6 27 24.2% 0.94 [0.33, 2.68] 1 33 8 32 34.8% 0.12 [0.02, 0.91] 3 45 1 28 5.3% 1.87 [0.20, 17.07] 1 24 0 26 2.1% 3.24 [0.14, 75.91] 3 20 6 30 20.5% 0.75 [0.21, 2.66] 178 194 100.0% 0.85 [0.49, 1.48] 18 25 63, df = 5 (P = 0.25); l² = 25%	Events Total Events Total Weight M-H, Fixed, 95% Cl M-H, Fix 5 32 4 51 13.2% 1.99 [0.58, 6.87] 5 24 6 27 24.2% 0.94 [0.33, 2.68] 1 33 8 32 34.8% 0.12 [0.02, 0.91] 3 45 1 28 5.3% 1.87 [0.20, 17.07] 1 24 0 26 2.1% 3.24 [0.14, 75.91] 3 20 6 30 20.5% 0.75 [0.21, 2.66] 178 194 100.0% 0.85 [0.49, 1.48] 18 25 33, df = 5 (P = 0.25); 2 = 25% 0.01 0.1	Events Total Events Total Weight M-H, Fixed, 95% CI M-H, Fixed, 95% CI 5 32 4 51 13.2% 1.99 [0.58, 6.87] 5 24 6 27 24.2% 0.94 [0.33, 2.68] 1 33 8 32 34.8% 0.12 [0.02, 0.91] 3 45 1 28 5.3% 1.87 [0.20, 17.07] 1 24 0 26 2.1% 3.24 [0.14, 75.91] 3 20 6 30 20.5% 0.75 [0.21, 2.66] 178 194 100.0% 0.85 [0.49, 1.48]


Supplementary Figure S1: Weekly versus three weekly cisplatin CRT with toxicity grade ≥3 neutropenia.




Supplementary Figure S2: Weekly versus three weekly cisplatin CRT with toxicity grade ≥3 thrombocytopenia.




Supplementary Figure S3: Weekly versus three weekly cisplatin CRT with toxicity grade ≥3 anemia.



Supplementary Figure S4: Weekly versus three weekly cisplatin CRT with toxicity grade ≥3 nausea/vomiting.



Supplementary Figure S5: Weekly versus three weekly cisplatin CRT with toxicity grade ≥3 dermatitis.



Supplementary Figure S6: Weekly versus three weekly cisplatin CRT in receiving cisplatin dose $\geq 200 \text{mg/m}^2$.